Related Experiment Videos
Microangiopathy without hemolysis in a patient following allogeneic bone marrow transplantation
H Akiyama1, H Yoshinaga, M Endou
1Hematology Division, Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, Japan.
Abstract:
Thrombotic microangiopathy (TMA) is one of the complications of bone marrow transplantation (BMT) which includes hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Red cell fragmentation is the most consistent laboratory finding. We present a case of TMA with endothelial damage but without the signs of hemolysis. The patient was not receiving cyclosporine. Partial activation of platelets was also observed. This case represents a new form of TMA in transplant recipients.
Insights
Thrombotic microangiopathy (TMA) can occur after bone marrow transplantation (BMT). This case shows TMA with endothelial damage but no hemolysis, suggesting a new form in transplant recipients.
Area of Science:
- Hematology
- Transplantation Medicine
- Nephrology
Background:
- Thrombotic microangiopathy (TMA), encompassing hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), is a known complication of bone marrow transplantation (BMT).
- Red blood cell fragmentation is typically observed in TMA.
- Cyclosporine is a common medication associated with TMA post-BMT.